Lilly Cuts Forecast After U.S. Covid Drug Order Cancelled
Apr 28 2021, 5:25 AM
April 27 2021, 9:05 PM
April 28 2021, 5:25 AM
(Bloomberg) Eli Lilly & Co. cut the high end of its 2021 forecast after the U.S. canceled an order for the drugmakerâs solo Covid-19 antibody to focus on its combination treatment.
(Bloomberg) Eli Lilly & Co. cut the high end of its 2021 forecast after the U.S. canceled an order for the drugmakerâs solo Covid-19 antibody to focus on its combination treatment.
Adjusted earnings will top out at $8 a share, Indianapolis-based Lilly said Tuesday in a statement, down from an earlier maximum of $8.40. The company shaved the high end of its 2021 revenue forecast to $27.6 billion from $28 billion.
Proposed Indiana voting law change faces corporate criticism
TOM DAVIES, Associated Press
FacebookTwitterEmail
INDIANAPOLIS (AP) One of Indiana’s most prominent corporations is criticizing an Indiana proposal that opponents maintain will make mail-in voting more difficult by requiring voters to submit identification numbers with their ballot applications.
The bill’s Republican sponsors say it is aimed at preventing voter fraud by having similar voter ID requirements for mail voting as the state has for in-person voting at polling sites.
Stephen Fry, Eli Lilly and Co.’s senior vice president for human resources and diversity, told a legislative committee Tuesday that the company believed the bill wasn’t needed and that state officials acted correctly to allow no-excuse mail-in voting for the spring 2020 primary because of COVID-19 concerns. The Indiana bill is among a wave of GOP-backed election proposals that were introduced in states around the country after former P
The combination therapy from from Eli Lilly & Corecognizes the coronavirus and attaches to it, which blocks the pathogen from entering cells and spreading throughout the body.
WASHINGTON — Eli Lilly & Co.’s combination antibody drug for COVID-19 was cleared for emergency use by U.S. regulators, providing doctors with a treatment option that is expected to be
The EUA for Eli Lilly brings to patients a second antibody cocktail, following the FDA’s fall authorization of an antibody combination from Regeneron Pharmaceuticals. Lilly is working with Amgen to ramp up manufacturing of its newly authorized therapy.